Jennifer Meeuwsen
Executive Vice President, EVERSANA COMPLETE Commercialization
Expertise:
Jennifer is the Executive Vice President of Complete Commercialization at EVERSANA, a leading provider of commercialization services to the life sciences industry. Her robust background includes more than two decades of market access strategies and commercialization across the life sciences and biotech industries.
Over her career, she has played a pivotal role in helping pharmaceutical companies successfully launch and sustain their products in the market. Her expertise includes amplifying unmet needs and highlighting value propositions to stakeholders, ensuring that new medications achieve their full potential. At EVERSANA, she oversees the company’s COMPLETE Commercialization solution, helping emerging pharmaceutical and biotech companies leverage the full suite of EVERSANA services to bring a product to market.
Prior to EVERSANA, she held senior commercialization roles at several biotech companies, including Integra Connect, Decipher Biosciences and Myriad Genetics. She began her career in business development and marketing roles in the pharmaceutical industry.
Jennifer holds a bachelor’s degree in marketing and international business from Western Michigan University.
Articles by Jennifer Meeuwsen
Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency
In an EVERSANA-led discussion, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key Challenges: 3x lower net revenue than experienced launchers $247M average launch cost 24-month prep timeline 78% of small-cap companies face delays or rejections Solutions […]
Webinar: Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency
In a recent EVERSANA webinar, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key challenges: 3x lower net revenue than experienced launchers $247M average launch cost 24-month prep timeline 78% of small-cap companies face delays or rejections […]
Beyond Theory: Integrated Commercialization Model Proves Valuable in Launch Success
Unlock the Future of Drug Commercialization Discover the Proven Strategies Behind Successful Drug Launches Are you ready to revolutionize your drug commercialization approach? Download our exclusive whitepaper, “Beyond Theory: Integrated Commercialization Model Proves Valuable in Launch Success,” and gain insights from industry leaders at EVERSANA. What You’ll Learn: Comprehensive Outsourcing Strategies: Explore how EVERSANA COMPLETE Commercialization® offers both […]